GENEVA – Swiss drugmaker Roche Holding AG has posted a net profit drop of 7 percent compared with a year ago, weighed down by a strong Swiss franc and charges from one of its diagnostic units.
Continue Reading Below
The world's biggest manufacturer of cancer drugs, which reports earnings every six months, posted 5.641 billion Swiss francs ($6.25 billion) in net income from April to June, down from 6.047 billion francs in the comparable period of 2013.
The Basel, Switzerland-based company on Thursday reported first-half sales were 22.974 billion francs, down 1 percent from 23.295 billion francs from a year ago.
It reported impairment charges of 414 million francs in tissue diagnostics and said the stronger Swiss franc in the first half of the year, particularly against the dollar, was "strongly negative on the results."